DOUBLE MARKER – FIRST TRIMESTER(DOUBLE MARKER FIRST TRIMESTER 8-13 WEEK (FMF CERTIFIED)0

Name: DOUBLE MARKER - FIRST TRIMESTER(DOUBLE MARKER FIRST TRIMESTER 8-13 WEEK (FMF CERTIFIED)0
SKU: DOUBLE
Availability: InStock

Original price was: ₹2,607.00.Current price is: ₹2,500.00.

The first-trimester double marker test is a non-invasive prenatal blood test that checks for elevated levels of Free Beta-hCG and PAPP-A, two hormones or proteins that can indicate a higher risk of chromosomal abnormalities like Down syndrome, Edward syndrome, and Patau syndrome in the developing baby. The test provides a risk assessment, not a diagnosis, and is performed between weeks 9 and 13 of pregnancy, ideally combined with a nuchal translucency (NT) ultrasound for increased accuracy. High-risk results are typically followed up with more definitive diagnostic tests such as Non-Invasive Prenatal Testing (NIPT) or amniocentesis.

Purpose

To assess the risk of chromosomal abnormalities, specifically Down syndrome (Trisomy 21), Edward syndrome (Trisomy 18), and Patau syndrome (Trisomy 13).

To provide early information for making informed decisions about the pregnancy.

Key Components

Free Beta-hCG: A hormone whose levels are often higher in pregnancies with Down syndrome.

PAPP-A (Pregnancy-Associated Plasma Protein-A): A protein supporting fetal and placental development; lower levels can be associated with chromosomal abnormalities.

Maternal Age & Gestational Age: These factors are included in the risk calculation.

Procedure

Blood Draw: A blood sample is taken from the pregnant woman.

Nuchal Translucency (NT) Scan: An ultrasound is performed to measure the fluid-filled space at the back of the baby’s neck; a larger NT measurement can indicate a higher risk.

Combined Risk Calculation: The blood test results are combined with the NT scan findings and maternal age to calculate the overall risk.

Interpretation & Next Steps

Screening Test:

The double marker test is a screening tool, not a diagnostic one; it provides a risk assessment, not a definitive diagnosis.

Low-Risk Result:

Indicates a low likelihood of the baby having the screened chromosomal abnormalities.

High-Risk Result:

Suggests a higher probability of chromosomal abnormality and warrants further diagnostic testing.

Follow-Up Tests:

Confirmatory diagnostic tests like NIPT, amniocentesis, or chorionic villus sampling (CVS) may be recommended.

Request Callback & whatsapp +919092026085

SKU: DOUBLE Categories: Laboratory, Routine Profile Tag: TRIPLE

Description
Additional information

Description

Method:	ECLIA, FMF Certified
Comment:	For Combined Risk Assessment (Biochemical risk + Nuchal translucency) kindly enclose Ultrasound report between 11-13 weeks + 6 days gestation including CRL, NT & Nasal Bone.
Price:	2600.00
Report:	Sample Mon through Sat by 11 am; Report Same day
Usage:	Aneuploidies are major causes of perinatal death and childhood handicap. Maternal serum screening test is an effective screening method for detection of major aneuploidies like Trisomy 21 & Trisomy 18/13 in the first trimester of pregnancy. Detection rate for Down syndrome is 60% with a false positive rate of 5% if only biochemical risk is estimated. A combination of Nuchal translucency and biochemical tests (Combined test) has detection rate of Down syndrome 82 to 87% at 5% false positive rate. Addition of absent nasal bone status can improve detection rate up to 93% at false positive rate of 2.5%.
Doctor Specialty:	Gynecologist
Disease:	Prenatal Diagnosis
Components:	PAPP-A Free Beta HCG *Risk Evaluation
Courier Charges:	0.00
Home Collection:	Available
Department:	IMMUNOASSAY
Pre Test Information:	Provide maternal Date of birth (dd/mm/yy); LMP or Ultrasound; Number of Fetuses (Single/Twins); Diabetic status and Body Weight in Kg, IVF, Smoking & Previous history of Trisomy 21 pregnancy. Duly filled Maternal Serum Screen requisition form (Form 11) is mandatory. Acceptable between 9 to 13 weeks + 6 days gestation.